| 10.235 0.145 (1.44%) | 08-21 14:42 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.68 | 1-year : | 13.63 |
| Resists | First : | 10.86 | Second : | 11.67 |
| Pivot price | 10.56 |
|||
| Supports | First : | 9.55 | Second : | 7.94 |
| MAs | MA(5) : | 9.95 |
MA(20) : | 10.7 |
| MA(100) : | 9.54 |
MA(250) : | 7.49 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.6 |
D(3) : | 23.9 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 12.1 | Low : | 4.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ICCC ] has closed above bottom band by 27.2%. Bollinger Bands are 29.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.27 - 10.33 | 10.33 - 10.38 |
| Low: | 9.64 - 9.71 | 9.71 - 9.76 |
| Close: | 10 - 10.1 | 10.1 - 10.19 |
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Fri, 21 Aug 2026
ImmuCell Corporation (ICCC) Q2 2026 Earnings: Settlement Helped the Quarter, but Margin Repair Still Matters More - AlphaStreet
Thu, 20 Aug 2026
ImmuCell (ICCC) Q2 2026 Earnings Call Transcript - AOL.com
Sun, 16 Aug 2026
How (ICCC) Movements Inform Risk Allocation Models - Stock Traders Daily
Fri, 14 Aug 2026
ImmuCell (ICCC) Q2 2026 Earnings Call: Sales Rise 11.5%, Capacity Expansion Planned - TradingKey
Fri, 14 Aug 2026
ImmuCell Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ICCC) 2026-08-14 - Seeking Alpha
Thu, 13 Aug 2026
ImmuCell Plans About $4.5M Expansion for Calf Health Products - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 32.1 (%) |
| Held by Institutions | 21.8 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.22 |
| Profit Margin | -1.9 % |
| Operating Margin | 19 % |
| Return on Assets (ttm) | 4.5 % |
| Return on Equity (ttm) | -1.9 % |
| Qtrly Rev. Growth | 28.3 % |
| Gross Profit (p.s.) | 1.4 |
| Sales Per Share | 3.3 |
| EBITDA (p.s.) | 0.64 |
| Qtrly Earnings Growth | 31.2 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -144.43 |
| PEG Ratio | 0 |
| Price to Book value | 3.13 |
| Price to Sales | 3.05 |
| Price to Cash Flow | 20.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|